What is Peptide YY?
Peptide YY is a gut-hormone family involved in feeding regulation. The selected trial studied PYY3-36 alone and with GLP-1; the combined result should not be described as a proven PYY-alone effect.
Biological role or research focus
Acute appetite signaling.
An acute combined-hormone effect cannot be transferred to PYY alone or interpreted as sustained weight loss.
Role reference: Effects of PYY3-36 and GLP-1 on energy intake, energy expenditure, and appetite in overweight men. · 2014 ↗
Names you may encounter
PYY · PYY3-36 · PYY 3-36
Search terms can include brands, combinations, or historical names. They are not automatic product equivalents.
- Class / identity
- Gut hormone family; PYY forms must be distinguished
- Research focus
- Acute appetite signaling
- Featured evidence
- Human randomized crossover study
- Source check
- October 4, 2026
Quick answers
- Is Peptide YY FDA approved?
- No. No FDA-approved drug contains Peptide YY. Source ↗
- Is Peptide YY safe?
- Not an approved drug. Human studies of PYY3-36 found nausea and vomiting, which led many participants in one weight-loss trial to stop; long-term safety is unknown. Human safety data: trials only. The Risks & interactions section below lists what is known. Read the risks ↓
- Is Peptide YY banned in sport?
- Very likely. The 2026 World Anti-Doping Agency (WADA) Prohibited List does not name it, but it appears to fall under a banned class (S0 Non-approved substances). Source ↗
What does the evidence show?
Evidence map
Every study featured on this page, grouped by what was actually tested. Human studies count most; animal and cell results often do not carry over to people.
| Study | Type | Population / model |
|---|---|---|
| PYY3-36 with and without GLP-1 (2014) | Human randomized crossover study | 25 overweight healthy men. |
Selected published evidence, with the population, findings, and limits kept together. These original summaries draw on publication abstracts; they are not a systematic review.
Human randomized crossover study · 2014
PYY3-36 with and without GLP-1
What did this publication test, and what did it find?
- Population / model
- 25 overweight healthy men.
- Study design
- Randomized double-blind four-condition crossover comparing PYY3-36, GLP-1, their combination, and placebo.
- Main finding
- Neither individual infusion significantly reduced food intake in this experiment. The combination reduced intake by 30.4%; nausea increased slightly.
- Limits & context
- An acute combined-hormone effect cannot be transferred to PYY alone or interpreted as sustained weight loss.
Read the original paper for methods, adverse events, funding, and conflicts of interest. Publisher access may require a subscription.
Registered human trials
13 registered studies name Peptide YY as an intervention; 0 are recruiting or under way, 0 have not started recruiting yet, 11 completed and 2 ended early, were withdrawn or have another status. Checked November 16, 2026 on ClinicalTrials.gov.
| Study | Status | Phase | Start | People |
|---|---|---|---|---|
| L-Cell Activity in Small Intestine as Biliopancreatic Loop in Obese Patients With DM2 Submitted to RYGBP NCT05446415 · University of Sao Paulo General Hospital | Status unknown | Not applicable | 2020-02-05 | 20 |
| APPETITE: linguAl PYY3-36 on aPpEtite and acuTe Energy InTakE NCT05110664 · University College, London | Status unknown | 2022-02 | 40 | |
| Macronutrient Regulation of Ghrelin and Peptide YY NCT02464514 · Duke University | Completed | Not applicable | 2004-01 | 28 |
| Role of the Gut Sweet Taste Receptor in the Secretion of Glucagon-like Peptide-1 and Peptide YY NCT01304823 · University Hospital, Basel, Switzerland | Completed | Phase 1 | 2010-06 | 10 |
| Degradation of the Anorexic Hormone Peptide YY NCT02493959 · Hvidovre University Hospital | Completed | Early phase 1 | 2014-05 | 8 |
| Effects of Intravenous Infusions of Gut Hormones on Appetite and Metabolism. NCT00940134 · University of Copenhagen | Completed | Not applicable | 2011-03 | 24 |
| Sweet Taste Receptors and the Secretion of Glucagon-like Peptide-1 and Peptide YY NCT01088841 · University Hospital, Basel, Switzerland | Completed | Phase 1 | 2009-04 | 16 |
| The Role of Peptide YY (PYY)Infusions in Inhibiting Food Intake. NCT00259246 · University of Copenhagen | Completed | Not applicable | 2004-06 | 24 |
A registration shows a study was planned; it is not a result. Some studies use the compound only as a comparison or in a combination. All 13 listed studies.
Further reading · 4 additional publication links
Exact-name PubMed search checked 2026-10-04. These records have not been appraised. A name match can include related compounds, combinations, or other formulations; it does not establish safety or benefit.
Peptide YY. ↗
Current opinion in endocrinology, diabetes, and obesity · 2008 Feb · Evaluation Study, Journal Article, Review
Peptide YY: A Paneth cell antimicrobial peptide that maintains Candida gut commensalism. ↗
Science (New York, N.Y.) · 2023 Aug 4 · Journal Article
Read available full text ↗
Virilizing insulinoma. ↗
Endokrynologia Polska · 2025 · Journal Article, Case Reports
Bariatric Surgery: It's Not Just Incretins! ↗
The Journal of clinical endocrinology and metabolism · 2022 Jan 18 · Editorial, Research Support, N.I.H., Extramural, Comment
Read available full text ↗
Risks & interactions
Not an approved drug. Human studies of PYY3-36 found nausea and vomiting, which led many participants in one weight-loss trial to stop; long-term safety is unknown.
Evidence comes from short infusion experiments and one multicenter weight-loss trial. Nausea and vomiting limited tolerability, and no long-term safety data were found.
It isn't approved, so there is no official list of who should avoid it, and its human studies are too small to show who is most at risk. No condition is tagged, but that does not make it safe for anyone. If a condition applies to you, talk to a doctor or pharmacist first.
Who should not use it
There is no official list, because it has never been approved as a medicine. That is not a sign it is safe for anyone: its risks have not been studied enough to know who is most at risk.
Serious risks
- In a multicenter weight-loss trial, 59% of the highest-exposure group stopped because of nausea and vomiting
Side effects reported in studies
- nausea
- vomiting
Summarized from published studies with AI assistance; not reviewed by a clinician. Not a complete list, and not medical advice: talk to a doctor or pharmacist about your own situation. Checked 2026-10-10. Sources: Efficacy and safety of PYY3-36 for weight reduction in obese adults (2007) ↗ · PYY3-36 and GLP-1 in overweight men (2014) ↗
Safety & what remains unknown
Nausea and route-specific tolerability matter. A brief controlled infusion cannot establish chronic safety.
Evidence boundaries
An acute combined-hormone effect cannot be transferred to PYY alone or interpreted as sustained weight loss.
Regulatory status
- U.S. FDA approval
- Not approved
No FDA-approved drug containing this substance found in Drugs@FDA (openFDA data updated 2026-10-07). source - FDA compounding (503A bulk list)
- Not on FDA’s compounding lists
Not found on FDA's 503A category 1, 2 or 3 lists (updated May 14, 2026) or the category 2 safety-risk page (updated April 22, 2026). source - World Anti-Doping Agency (2026)
- Likely prohibited under a class rule · S0 Non-approved substances
Not named. S0 prohibits (at all times) any pharmacological substance not covered by another section and with no current approval by any government health authority for human therapeutic use; no such approval was found, so it is likely covered. source
Checked October 28, 2026. Rules change; follow the source links for the current status. Regulatory tracker.
This is not a complete list of contraindications, interactions, or adverse effects. Medicine labels apply to specific products and indications; research-use listings are not interchangeable with approved medicines.
Research context & identity
This profile concerns short-term infusion physiology in overweight men, rather than a demonstrated chronic weight-management treatment.
New editorial updates
New source discoveries
Links appear automatically. Unreviewed discoveries are not verified medical findings.
Sources & supplier listings
Listings are grouped by the vendor’s stated identity. Blends and modified derivatives are labeled separately. Inclusion is not a quality assessment or an endorsement.
We have not added a supplier for this profile. Missing products and coded listings are not filled with guesses.
Biology & proposed mechanism
The study evaluated whether two gut-hormone signals interact in controlling acute intake. PYY1-36 and PYY3-36 are distinct forms with different receptor contexts.
Questions worth asking
- Did PYY3-36 alone significantly reduce intake in this trial?
- What material, population, and route were actually studied?
- An acute combined-hormone effect cannot be transferred to PYY alone or interpreted as sustained weight loss.
- What adverse effects, uncertainty, and conflicts of interest does the original source report?
Frequently asked questions
Did PYY3-36 alone significantly reduce intake in this trial?
No. The significant intake reduction was observed with the combination, not either individual infusion.
Does the publication verify a supplier’s product?
No. The tested material and a commercial listing need separate identity and batch checks. A research-use disclaimer does not establish clinical suitability.
References & editorial record
Source notes checked 2026-10-04. Original PepsRadar summaries. Not reviewed by a medical professional. Topic grouping is editorial navigation, not a treatment recommendation.
